The use of cardiac glycosides in the Netherlands has been steadily declining over the past decade. From a high of 2.7 units per thousand persons per day in 2013, the usage fell to 1.5 units by 2023. This represents a significant decrease, characterized by a series of annual declines, particularly sharp in 2019 with a year-on-year drop of 19.05%. The last five years saw an average annual decline of -6.51%.
Looking ahead, the forecasted data suggests a continued downward trend, with expected usage of 1.2 units per thousand persons per day by 2028, implying an average annual decrease of -4.36%. This forecasted trend points to a 20% reduction over the next five years.
Future trends to watch for include:
- Developments in alternative treatments for cardiac conditions that may further reduce the reliance on cardiac glycosides.
- Regulatory changes and healthcare policy adjustments that could impact prescription patterns.
- Innovation in pharmaceutical therapies aimed at cardiovascular diseases.
